Home Meeting notice Poxel announces the convening of its annual general meeting to be held on June 21, 2022

Poxel announces the convening of its annual general meeting to be held on June 21, 2022

0

Lyon, FrancePOXEL S.A. (Euronext: POXELS – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication of the notice of meeting of the General Meeting which will stand on June 21, 2022 to 9:00 a.m. EST to University hotel5 Place Saint-Paul, 69005 LYON.

The notice of meeting, the notice of meeting, the 2021 Universal Registration Document and the documents and information mentioned in article R.22-10-23 of the Commercial Code will be made available to shareholders on the Company’s website at least 21 days before the Meeting at the following link: https://www.poxelpharma.com/en_us/investors/shareholder-information/annual-general-meeting-documents

Shareholders can vote personally on the day of the Meeting, but can also vote by post or by proxy without personally attending the Meeting, as follows: by post using the voting form; or by giving proxy to the Chairman of the General Meeting or to any other natural or legal person.

The detailed procedures for remote participation and the prior sending of written questions are available in the notice of meeting n-degré57 published in the BALO of May 13, 2022.

The results and presentation of the 2022 General Assembly will be available on At Poxel website www.poxelpharma.com in the Investors/ Shareholder Information/ General Meeting Documents section after the Meeting.

On Poxel S.A.

Poxella is a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare diseases. Poxella has clinical and early-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is undergoing a simplified phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the Company intends to initiate Phase 2a proof-of-concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG (Imeglimin), At Poxel first-in-class lead product that targets mitochondrial dysfunction, was approved and launched for the treatment of type 2 diabetes in Japan. Poxella expects to receive royalties and payments based on the sales of Sumitomo Pharma. Poxella Sumitomo Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate additional growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxella has its headquarters at Lyon, Franceand has subsidiaries in Boston, MAand Tokyo, Japan.

For more information, visit: www.poxelpharma.com

Contact:

Investor / Media

Aurelie Bozza

Senior Director of Investor Relations and Communications

E: [email protected]

Tel: +33 6 99 81 08 36

(C) 2022 electronic news edition, source ENP Newswire